CStone Pharmaceuticals Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	269.58	407.21	463.84	481.36	243.72
Revenue	269.58	407.21	463.84	481.36	243.72
Revenue Growth (YoY)	-33.80%	-12.21%	-3.64%	97.51%	-76.54%
Cost of Revenue	218.34	167.05	159.55	202.99	106.83
Gross Profit	51.25	240.15	304.3	278.38	136.89
Selling, General & Admin	172.36	211.58	382.06	576.36	661.38
Research & Development	311.5	123.93	501.4	614.16	1,305
Operating Expenses	483.87	335.51	883.46	1,191	1,966
Operating Income	-432.62	-95.36	-579.16	-912.15	-1,829
Interest Expense	-13.27	-15.17	-11.82	-8.48	-2.24
Interest & Investment Income	-	12.67	24.89	9.67	9.8
Currency Exchange Gain (Loss)	-	-2.8	20.36	61.49	-69.13
Other Non Operating Income (Expenses)	21.95	13.44	25.71	8.71	36.02
EBT Excluding Unusual Items	-423.94	-87.22	-520.02	-840.75	-1,855
Gain (Loss) on Sale of Investments	-	6.36	0.3	-61.93	-64.2
Gain (Loss) on Sale of Assets	-	0.38	178.89	-	-0.9
Asset Writedown	-	-10.73	-26.4	-	-
Pretax Income	-423.94	-91.21	-367.23	-902.68	-1,920
Income Tax Expense	13.06	-	-	-	-
Earnings From Continuing Operations	-437	-91.21	-367.23	-902.68	-1,920
Net Income	-437	-91.21	-367.23	-902.68	-1,920
Net Income to Common	-437	-91.21	-367.23	-902.68	-1,920
Shares Outstanding (Basic)	1,410	1,276	1,263	1,173	1,165
Shares Outstanding (Diluted)	1,410	1,276	1,263	1,173	1,165
Shares Change (YoY)	10.46%	1.04%	7.69%	0.66%	11.39%
EPS (Basic)	-0.31	-0.07	-0.29	-0.77	-1.65
EPS (Diluted)	-0.31	-0.07	-0.29	-0.77	-1.65
Free Cash Flow	-	-343.18	-588.86	-610.74	-1,575
Free Cash Flow Per Share	-	-0.27	-0.47	-0.52	-1.35
Gross Margin	19.01%	58.98%	65.60%	57.83%	56.17%
Operating Margin	-160.48%	-23.42%	-124.86%	-189.49%	-750.64%
Profit Margin	-162.10%	-22.40%	-79.17%	-187.53%	-787.84%
Free Cash Flow Margin	-	-84.28%	-126.95%	-126.88%	-646.26%
EBITDA	-419.33	-82.06	-560.24	-895.41	-1,821
EBITDA Margin	-155.55%	-20.15%	-120.78%	-186.01%	-
D&A For EBITDA	13.3	13.3	18.93	16.74	8.76
EBIT	-432.62	-95.36	-579.16	-912.15	-1,829
EBIT Margin	-160.48%	-23.42%	-124.86%	-189.49%	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.